Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (131-140 of 219) with videos related to

Pageof 22
Sort By:
Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Dermatology and Therapy|March 6, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Journal of the American Academy of Dermatology|October 18, 2023
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trialJoseph F Merola, Lawrence Charles Parish, Lyn Guenther, et al.
Dermatology and Therapy|February 5, 2025
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 MonthsDiamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, et al.
Dermatology and Therapy|May 6, 2025
Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 MonthsDiamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, et al.
Journal of the American Academy of Dermatology|September 20, 2020
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)Mark Lebwohl, Leon Kircik, Jean-Philippe Lacour, et al.
Dermatology and Therapy|July 17, 2025
Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-AnalysisKim A Papp, Ron Vender, Kerri Purdy, et al.
Dermatology and Therapy|October 22, 2025
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with VitiligoDavid Rosmarin, Amit G Pandya, Thierry Passeron, et al.
Clinical and Experimental Dermatology|May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trialStephen Tyring, Angela Moore, Akimchi Morita, et al.
Lancet (London, England)|June 10, 2017
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Pageof 22

Showing results (131-140 of 219) with videos related to

Sort By:
Pageof 22
Dermatology and Therapy|July 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Dermatology and Therapy|March 6, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 TrialsApril W Armstrong, Matthias Augustin, Jennifer L Beaumont, et al.
Journal of the American Academy of Dermatology|October 18, 2023
Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trialJoseph F Merola, Lawrence Charles Parish, Lyn Guenther, et al.
Dermatology and Therapy|February 5, 2025
Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 MonthsDiamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, et al.
Dermatology and Therapy|May 6, 2025
Correction: Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 MonthsDiamant Thaçi, Mamitaro Ohtsuki, Julia-Tatjana Maul, et al.
Journal of the American Academy of Dermatology|September 20, 2020
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)Mark Lebwohl, Leon Kircik, Jean-Philippe Lacour, et al.
Dermatology and Therapy|July 17, 2025
Time to Onset of Action for Biologics and Targeted Treatments in Psoriasis: Systematic Targeted Literature Review and Network Meta-AnalysisKim A Papp, Ron Vender, Kerri Purdy, et al.
Dermatology and Therapy|October 22, 2025
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with VitiligoDavid Rosmarin, Amit G Pandya, Thierry Passeron, et al.
Clinical and Experimental Dermatology|May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trialStephen Tyring, Angela Moore, Akimchi Morita, et al.
Lancet (London, England)|June 10, 2017
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trialsKristian Reich, Kim A Papp, Andrew Blauvelt, et al.
Pageof 22